CHEMOTHERAPY REGIMEN ID: IMT3 (Updated 07/05/2023)
Inflammatory Myofibroblastic Tumor (IMT) with ALK Translocation
Brigatinib
Referenced with permission from the NCCN. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines available at: https://www.nccn.org/. Accessed April 2, 2025 ©National Comprehensive Cancer Network, 2025. Any clinician seeking to apply or consult any NCCN content is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding the NCCN Content, their use and disclaims any responsibility for their application in any way.
EBSCO Information Services accepts no liability for advice or information given herein or errors/omissions in the text. It is merely intended as a general informational overview of the subject for the healthcare professional.
DynaMed Levels of Evidence
Quickly find and determine the quality of the evidence.
DynaMed provides easy-to-interpret Level of Evidence labels so users can quickly find and determine the quality of the best available evidence. Evidence may be labeled in one of three levels:
1Level 1 (likely reliable) Evidence
2Level 2 (mid-level) Evidence
3Level 3 (lacking direct) Evidence
Grades of Recommendation
Guideline producers are now frequently using classification approaches for their evidence and recommendations, and these classifications are recognized and requested by guideline users. When summarizing guideline recommendations for DynaMed users, the DynaMed Editors are using the guideline-specific classifications and providing guideline classification approach when this is done.
Download the full version of Levels of Evidence